Drug Profile
Research programme: cell-based cardiovascular therapies - U.S. Stem Cell
Alternative Names: AlloCell; Allogeneic stem cell therapy - U.S. Stem Cell; BioPace; Cell-based heart damage therapies - U.S. Stem Cell; Cell-based sino-atrial dysfunction disease therapy - U.S. Stem Cell; Locally™Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bioheart
- Developer U.S. Stem Cell
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Arrhythmias; Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Arrhythmias in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 17 Mar 2014 Bioheart and Magnum Cell Therapies enter into a joint venture